Is testosterone therapy indicated for adult women with hypoactive sexual desire disorder who have not responded to estrogen therapy?

Testosterone Therapy for Women with HSDD

Yes, testosterone therapy is indicated for postmenopausal women with hypoactive sexual desire disorder (HSDD) who have undergone formal biopsychosocial assessment, and this remains the only evidence-based indication for testosterone use in women. 1

Primary Indication and Patient Selection

The 2019 Global Consensus Position Statement establishes that the sole evidence-based indication for testosterone in women is treatment of postmenopausal women diagnosed with HSDD after formal biopsychosocial assessment 1. This applies whether or not the patient is taking concurrent estrogen therapy.

Who Qualifies:

• Postmenopausal women (natural or surgical menopause) with distressing low sexual desire 1
• Women who have completed comprehensive evaluation ruling out:
  • Relationship difficulties
  • Psychological distress
  • Physical illness
  • Medication side effects
  • Culturally/religiously-based sexual inhibition 1

Who Does NOT Qualify:

• Premenopausal women - insufficient evidence, though limited data suggest possible benefit in late reproductive age women 2
• Women with unaddressed biopsychosocial factors causing HSDD
• Women seeking testosterone for energy, cognition, bone health, or other non-sexual indications 3

Efficacy Data

The evidence shows modest but clinically meaningful benefit:

For postmenopausal women on estrogen therapy:

• Increase of approximately 1 additional satisfying sexual event per month compared to placebo 4
• 65-68% reduction in personal distress vs 40-48% with placebo 4
• Improvements across all sexual function domains (arousal, pleasure, orgasm, self-image) 4

For postmenopausal women NOT on estrogen:

• Increase of 2.12 satisfying sexual events per month with testosterone 300 mcg/day vs 0.73 with placebo 5
• 115% increase in orgasms vs 38% with placebo 4

Important Caveat on Formulations:

Two large phase III trials of transdermal testosterone gel (0.22 g/day) showed NO benefit over placebo 4, highlighting that formulation and dosing matter significantly.

Prescribing Recommendations

Formulation and Dosing:

Transdermal testosterone patch (TTP) 300 mcg/day is the best-studied and most effective formulation 4. However:

• No FDA-approved testosterone formulation exists for women 6, 3
• Off-label use of approved male formulations is reasonable if dosed to maintain physiologic female testosterone levels 1
• Avoid compounded "bioidentical" preparations unless no approved alternative exists, and only from pharmacies meeting Good Manufacturing Practice standards 1
• Never use testosterone pellets or injections - these produce supraphysiologic levels 1

Monitoring Protocol:

1. Baseline: Measure total testosterone before starting therapy 1

2. Early monitoring: Repeat testosterone level at 3-6 weeks after initiation 1

3. Ongoing monitoring:

   • Check testosterone level every 6 months 1
   • Assess for signs of androgen excess (acne, hirsutism, voice deepening)
   • Maintain levels in the physiologic premenopausal range 1

4. Treatment duration:

   • Discontinue if no benefit by 6 months 1
   • Safety data beyond 24 months are not available 1

Safety Profile

Short-term testosterone therapy (up to 24 months) in physiologic doses is not associated with serious adverse events 1:

• Does NOT increase mammographic breast density (Level I, Grade A) 1
• Does NOT appear to increase short-term breast cancer risk 1
• Most common side effects: unwanted hair growth (30% vs 23% placebo), acne 5
• Effects are generally mild and reversible 7

Critical Safety Limitations:

• Long-term safety data (>24 months) do not exist 1
• Trials excluded women at high cardiometabolic risk 1
• Four breast cancer cases occurred in testosterone-treated women in one large trial (vs zero in placebo), though timing suggests some were pre-existing 5
• Caution recommended in women with hormone-sensitive breast cancer 1

Clinical Algorithm

Step 1: Confirm postmenopausal status and HSDD diagnosis through biopsychosocial assessment

Step 2: Address modifiable factors first (relationship issues, mental health, medications)

Step 3: If HSDD persists, obtain informed consent discussing:

• Off-label use
• Modest benefit (1-2 additional satisfying events/month)
• Unknown long-term safety
• Need for monitoring

Step 4: Measure baseline total testosterone

Step 5: Prescribe transdermal testosterone targeting physiologic premenopausal levels (ideally 300 mcg/day patch if available)

Step 6: Recheck testosterone at 3-6 weeks, adjust dose to maintain physiologic range

Step 7: Assess clinical response and testosterone levels every 6 months

Step 8: Discontinue if no benefit by 6 months OR if androgen excess develops

Key Pitfalls to Avoid

• Do not use testosterone levels to diagnose HSDD - diagnosis is clinical, levels are only for monitoring 2
• Do not prescribe testosterone for premenopausal women outside of late reproductive age with severe symptoms (insufficient evidence) 1
• Do not use male-dosed formulations without adjustment - this causes supraphysiologic levels 1
• Do not continue beyond 6 months without clinical benefit 1
• Do not prescribe for non-sexual indications (fatigue, cognition, bone health) - no evidence 3

The Regulatory Gap

Despite decades of use and consistent evidence, no regulatory agency has approved testosterone for women, creating an access problem where patients must rely on off-label male formulations or unregulated compounded products 3, 7. This represents a significant unmet medical need requiring urgent attention from regulatory bodies.